CAJ | 학술논문

目的：评估利妥昔单抗在治疗免疫性血小板减少症中的临床应用价值及安全性。方法采用标准剂量和小剂量的利妥昔单抗单用或者联合其他治疗方法对2例初诊初治的免疫性血小板减少症患者，以及6例确诊复发难治免疫性血小板减少症患者进行治疗，分析其近期疗效，观察使用后的不良反应。结果2例初诊初治患者的近期疗效良好，1例6个月后复发。6例复发难治患者中4例有效（其中1例2年后复发），2例无效。所有患者均无明显近期不良反应。结论利妥昔单抗治疗免疫性血小板减少症，疗效显著，安全性及耐受性好。
목적：평고리타석단항재치료면역성혈소판감소증중적림상응용개치급안전성。방법채용표준제량화소제량적리타석단항단용혹자연합기타치료방법대2례초진초치적면역성혈소판감소증환자，이급6례학진복발난치면역성혈소판감소증환자진행치료，분석기근기료효，관찰사용후적불량반응。결과2례초진초치환자적근기료효량호，1례6개월후복발。6례복발난치환자중4례유효（기중1례2년후복발），2례무효。소유환자균무명현근기불량반응。결론리타석단항치료면역성혈소판감소증，료효현저，안전성급내수성호。
Objective To evaluate the effectiviness and safety of rituximab in the treatment of immune thrombocytopenia .Meth-ods Standard doses and small doses of rituximab alone or combined therapy with other methods were used in 2 cases with immune thrombocytopenia who diagnosed and treated for the first time ,and 6 cases who diagnosed with refractory recurrent immune throm-bocytopenia .The recent curative effect ,adverse reactions were analyzed .Results The recent curative effect was well in the 2 cases who diagnosed and treated for the first time ,but 1 case recurrenced after 6 months .4 cases of effective in the 6 cases who diagnosed with refractory recurrent ,in which 1 case recurrenced after 2 years ,2 cases had no effect .All of the patients have no obvious adverse reaction in the near future .Conclusion Rituximab treatment of immune thrombocytopenic ,it is of good curative effect ,good safety and tolerability .